STOCK TITAN

Biophytis resets shareholder meeting for November 27

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Biophytis SA (BPTSY) said its November 12, 2026 ordinary and extraordinary general meeting could not validly deliberate because quorum was not met. Shareholders present, represented, or voting remotely or by mail accounted for 12.46% of share capital, compared with required thresholds of 20% for ordinary business and 25% for extraordinary business. The meeting is reconvened with the same agenda for November 27, 2026, at 2:00 p.m.

At the second meeting, no quorum is required for the ordinary session; the extraordinary session requires shareholders present, represented, or voting remotely to hold at least 20% of voting shares. Mail-in ballots, proxies, and admission cards received for the first meeting remain valid. Biophytis intends to ask the President of the Paris Commercial Court to appoint an ad hoc proxy for absent shareholders, subject to the President’s sole discretion.

Share capital represented at first meeting 12.46% Shareholders present, represented, or voting remotely or by mail at the November 12, 2026 meeting
First-meeting ordinary-session quorum 20% Required for the ordinary portion of the November 12, 2026 meeting
First-meeting extraordinary-session quorum 25% Required for the extraordinary portion of the November 12, 2026 meeting
Second-meeting extraordinary-session quorum 20% Required share of voting shares for shareholders present, represented, or voting remotely
quorum regulatory
"unable to validly deliberate due to the lack of a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
ad hoc proxy regulatory
"appoint an ad hoc proxy to represent absent shareholders"
extraordinary session regulatory
"Shareholders present, represented, or voting remotely must hold at least one-fifth"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What quorum is required at Biophytis (BPTSY)’s second general meeting?

At the November 27, 2026 meeting, the ordinary session has no quorum requirement, while the extraordinary session requires shareholders present, represented, or voting remotely to hold at least 20% of voting shares. The first meeting’s required thresholds were 20% for ordinary business and 25% for extraordinary business.

Are votes already cast valid for Biophytis (BPTSY)’s reconvened meeting?

Yes. Mail-in ballots, proxies, and admission cards received for the November 12, 2026 meeting remain valid for the second meeting on November 27, 2026. Shareholders who have not yet voted are invited to do so as soon as possible under the procedures in the meeting notice.

Will an ad hoc proxy represent absent Biophytis (BPTSY) shareholders?

Biophytis intends to ask the President of the Paris Commercial Court to appoint an ad hoc proxy to represent absent shareholders and exercise their voting rights at the November 27, 2026 meeting. The appointment is subject to the President’s sole discretion; the proxy would split votes for and against according to predefined rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report: November 13, 2026

 

Commission File Number: 001-38974

 

BIOPHYTIS S.A.

(Translation of registrant’s name into English)

 

 

Stanislas Veillet
Biophytis S.A.

Silver Innov

54 rue Molière

94200 Ivry sur Seine, France

+33 1 76 28 40 83

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

x Form 20-F ¨ Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

On November 12, 2026, Biophytis S.A. issued a press release announcing that the ordinary and extraordinary general meeting convened for November 12, 2026, was unable to validly deliberate due to the lack of a quorum and that, in accordance with the law, the meeting is therefore reconvened, with the same agenda, on Friday, November 27, 2026, at 2:00 p.m. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

 

EXHIBIT LIST

 

Exhibit  Description
 99.1  Press Release dated November 12, 2026.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BIOPHYTIS S.A.
     
Date: November 13, 2026 By: /s/ Stanislas Veillet 
    Name: Stanislas Veillet
    Title: Chairman and Chief Executive Officer

 

 

 

Exhibit 99.1

 

 

General Meeting of November 12, 2026: Quorum Not Met

 

Notice of a second General Meeting on November 27, 2026

 

Paris (France) and Cambridge (Massachusetts, United States), November 13, 2026, at 7:00 a.m. – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), informs its shareholders that the ordinary and extraordinary general meeting convened for November 12, 2026, at 2:00 p.m. was unable to validly deliberate due to the lack of a quorum. Shareholders present, represented, or voting remotely or by mail accounted for 12.46% of the share capital, while the required quorum was 20% for the ordinary portion and 25% for the extraordinary portion.

 

In accordance with the law, the meeting is therefore reconvened, with the same agenda, on Friday, November 27, 2026, at 2:00 p.m., at the Silver Innov Building, 54 rue Molière, 94200 Ivry-sur-Seine. The notice of the second meeting will be published in the BALO on November 16, 2026.

 

What Changes with the Second Notice

 

·Ordinary session (including approval of the financial statements for fiscal year 2025): no quorum is required.
·Extraordinary session: Shareholders present, represented, or voting remotely must hold at least one-fifth (20%) of the voting shares.
·Votes Already Cast: Mail-in ballots, proxies, and admission cards received for the first meeting remain valid for the second meeting. Shareholders who have not yet voted are invited to do so as soon as possible, in accordance with the procedures outlined in the notice of meeting.

 

Consideration of appointing an ad hoc representative to represent absent shareholders at the general meeting

 

Given the low turnout observed, the Company intends to request that the President of the Paris Commercial Court appoint an ad hoc proxy to represent absent shareholders at the meeting on November 27, 2026, and to exercise the voting rights attached to the shares of absent shareholders.

 

This measure is intended to enable the meeting to reach the required quorum and to deliberate on the proposed resolutions, including those under the extraordinary portion of the agenda.

 

To ensure complete neutrality in the voting results, this proxy would split their votes between “for” and “against” according to predefined rules. This appointment is subject to the sole discretion of the President of the Paris Commercial Court.

 

The Company will keep its shareholders informed of any significant developments. Documents relating to the meeting are available on its website under the “General Meetings” section.

 

***

 

About Biophytis

 

Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule currently in development for muscular disorders (sarcopenia, Phase 3 ready to begin, and Duchenne muscular dystrophy, Phase 1-2 to begin), respiratory (COVID-19, Phase 2-3 completed), and metabolic diseases (obesity, Phase 2 to begin). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, in the United States, and in Brazil. The Company’s common stock is listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADSs (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

 

 

 

 

 

Disclaimer

 

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates," or the negative forms of these words or other comparable terms. These forward-looking statements are based on assumptions that Biophytis considers reasonable. However, there can be no assurance that the statements contained in these forward-looking statements will prove to be accurate, as they are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks that are not yet known to Biophytis or that are not currently considered material by Biophytis. Consequently, there are or will be significant factors that could cause actual results to differ materially from those indicated in these statements. Please also refer to the section titled “Risks and Uncertainties Facing the Company” in the company’s 2023 Annual Financial Report, available on the BIOPHYTIS website (www.biophytis.com) and as set forth in the “Risk Factors” section of Form 20-F and other forms filed with the SEC (Securities and Exchange Commission, USA). We do not undertake to publicly update or revise any forward-looking statements, whether as a result of new information, developments, or otherwise, unless required by law.

 

Biophytis Contact

 

Investor Relations

investors@biophytis.com

 

Media Contact

 

Antoine Denry:antoine.denry@taddeo.fr – +33 6 18 07 83 27

Nizar Berrada:nizar.berrada@taddeo.fr – +33 6 38 31 90 50

 

 

 

Filing Exhibits & Attachments

1 document

Keep reading